FiercePharmaOriginal article
{"a":[{"_":"Viatris runs into FDA roadblock after advertising on-the-go use of cystic fibrosis inhaler","$":{"href":"/marketing/viatris-runs-fda-roadblocks-after-advertising-go-use-cystic-fibrosis-inhaler","hreflang":"en"}}]}
RegulatorynegativeNegative
AI Analysis
Summary
The FDA has rebuked Viatris for a direct-to-consumer video that allegedly misled viewers about the on-the-go use of a cystic fibrosis inhaler, representing a regulatory setback for the company.
Outcome Details
FDA rebuked Viatris for direct-to-consumer advertising that allegedly misled viewers about a cystic fibrosis inhaler
Importance:4/10
Sentiment:
-0.70
regulatoryFDAadvertisingcystic fibrosisdirect-to-consumer
Related Companies
Read the original article
Published by FiercePharma on July 30, 2026 6:58 AM
